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Abstract
Interferon-β (IFN-β) is widely used to treat multiple sclerosis (MS), and its efficacy was
demonstrated in the setting of experimental autoimmune encephalomyelitis (EAE), an animal
model of MS; however, IFN-β is not effective in treating all cases of MS. Here, we demonstrate
that signaling by IFNAR (the shared receptor for IFN-α and IFN-β) on macrophages inhibits
activation of Rac1 and the generation of reactive oxygen species (ROS) through suppressor of
cytokine signaling 1 (SOCS1). The inhibition of Rac1 activation and ROS generation suppressed
the activity of the NLRP3 inflammasome, which resulted in attenuated EAE pathogenicity. We
further found that two subsets of EAE could be defined on the basis of their dependency on the
NLRP3 inflammasome and that IFN-β was not an effective therapy when EAE was induced in an
NLRP3 inflammasome–independent fashion. Thus, our study demonstrates a previously
uncharacterized signaling pathway that is involved in the suppression of EAE by IFN-β and
characterizes NLRP3-independent EAE, which cannot be treated with IFN-β.
INTRODUCTION
Type 1 interferons (IFNs), such as IFN-α and IFN-β, are involved in various aspects of
immune responses and the pathogenesis of various diseases. For example, IFN-β has been
used for more than 15 years as a first-line treatment for multiple sclerosis (MS). Study of an
animal model of MS, experimental autoimmune encephalomyelitis (EAE), has contributed
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to our understanding of the pathogenesis of MS, and three approved MS medications have
been directly developed from studies of EAE (1). Using the EAE model, we and another
group have shown that the inhibitory effect of IFN-β is mediated by innate immune cells,
such as macrophages and dendritic cells (DCs), which inhibit T helper 17 (TH17) responses
through interleukin-27 (IL-27) (2, 3). Other studies also demonstrated that type I IFNs
ameliorate EAE by reducing antigen presentation, inhibiting the proliferation of T cells,
altering the abundance of matrix metalloproteases, and altering cytokine responses through
signaling by the type I IFN receptor (IFNAR) in myeloid cells (4–6). Despite such basic
knowledge, the mechanisms of the occasional failure in IFN-β therapy are not clear.
Previous studies showed that IFN-β suppresses the production of IL-1β (7, 8). IL-1β
production is achieved in two steps. First, receptors [such as Toll-like receptor 4 (TLR4)
ligation by lipopolysaccharide (LPS)], and then pro–IL-1β is processed by inflammasomes
to form mature IL-1β (9). The Nod-like receptor (NLR) family, pyrin domain–containing 3
(NLRP3) inflammasome, on which we focus in this study, is a cytoplasmic sensor that is
activated by various pathogens and damage-associated molecules, including extracellular
adenosine triphosphate (ATP), nigericin, and monosodium urate (MSU) (9–12). How
IFNAR signaling represses the NLRP3 inflammasome was not clear except that signal
transducer and activator of transcription 1 (STAT1), a major downstream molecule of
IFNAR, mediates the signaling (8).
Here, we showed that IFN-β is effective only when EAE is developed in an NLRP3
inflammasome–dependent fashion. First, we demonstrated that type I IFNs inhibit activation
of the NLRP3 inflammasome in macrophages by decreasing the abundance of active Rac1
through a mechanism involving suppressor of cytokine signaling 1 (SOCS1). Rac1 is a small
G protein and a member of the Rac subfamily of the Rho family of guanosine
triphosphatases GTPases, which are involved in various cellular activities, such as
cytoskeletal reorganization, control of cell growth, and the activation of protein kinases.
Here, we demonstrated that IFNAR signaling induces SOCS1-mediated ubiquitination and
degradation of active Rac1. Reduction of active Rac1 decreased the production of
mitochondrial reactive oxygen species (ROS), resulting in inhibition of NLRP3
inflammasome activity. Second, we showed that EAE could develop independently of the
NLRP3 inflammasome and that such NLRP3 inflammasome–independent EAE does not
respond to IFN-β.
RESULTS
IFNAR signaling inhibits production of IL-1β
Activation of IFNAR signaling in innate immune cells results in various physiological
consequences. To identify the function of IFNAR signaling in innate immune cells, we
compared macrophages from wild-type mice and Ifnar1−/− mice. Because previous studies
have shown that IFNAR signaling is constitutively activated by low amounts of endogenous
type I IFNs, both in vivo and ex vivo (13, 14), the altered phenotypes of Ifnar1−/− cells
should be detected without adding exogenous type I IFN. We found that compared to wild-
type macrophages, Ifnar1−/− macrophages produced increased amounts of IL-1β upon
stimulation with LPS (see Materials and Methods) and ATP (Fig. 1A). In turn, under the
same conditions, recombinant IFN-α (rIFN-α) or rIFN-β suppressed the production of
IL-1β by wild-type macrophages (fig. S1, A to C). We also observed suppression of IL-1β
production by IFNAR signaling when cells were treated with either nigericin or MSU
(which activates the NLRP3 inflammasome) combined with LPS (9) (fig. S1, D to I). In
addition, rIFN-α suppressed the production of IL-18, another cytokine that is processed by
the NLRP3 inflammasome (fig. S1J). In contrast, IFNAR signaling did not inhibit IL-1β
production by macrophages stimulated with Salmonella typhimurium (fig. S1K), which
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activates the NLRC4 inflammasome (15). These results suggested that IFNAR signaling
inhibited cytokine production mediated by the NLRP3 inflammasome.
Activation of the NLRP3 inflammasome is inhibited by IFNAR signaling
We then tested whether deficiency in IFNAR impaired the production of pro–IL-1β by LPS;
however, the amounts of Il1b mRNA and pro–IL-1β protein were not increased in LPS-
treated Ifnar1−/− macrophages compared to those in LPS-treated wild-type macrophages
(fig. S2, A and B). Although we cannot rule out an indirect effect of type I IFN on the
production of pro–IL-1β at later time points, these results prompted us to investigate the
mechanism of the direct suppressive effect of IFNAR signaling on the NLRP3
inflammasome. We first evaluated NLRP3 inflammasome activity by measuring the amount
of caspase-1 p20, which reflects activated caspase-1 and the NLRP3 inflammasome, and we
found that the amount of p20 was increased in Ifnar1−/− macrophages compared to that in
wild-type macrophages (Fig. 1B). We also investigated whether Ifnar1−/− macrophages
showed increased oligomerization of the NLRP3 inflammasome complex by measuring the
numbers, stained areas, and intensity of caspase-1 foci, because the NLRP3 inflammasome
must oligomerize to be activated (16). ATP induced foci formation in wild-type and
Ifnar1−/− cells; however, quantitative analysis of confocal images showed that foci in
Ifnar1−/− cells were larger, more frequent, and had more staining intensity than those in
wild-type cells (Fig. 1, C and D). In agreement with this result, rIFN-α reduced the
frequency and intensity of foci formation in wild-type cells (fig. S3). In summary, our data
suggested that IFNAR signaling inhibited the activity of the NLRP3 inflammasome.
IFNAR signaling inhibits the generation of mitochondrial ROS
Next, we tried to identify the mechanism by which IFNAR signaling suppresses NLRP3
inflammasome activity. We first examined the expression of the genes Nlrp3, Asc, and
Casp1, which encode components of the NLRP3 inflammasome, but we found no difference
in their expression when we compared wild-type and Ifnar1−/− macrophages (fig. S4A). We
also found no alteration in the expression of Txnip (fig. S4A), which encodes thioredoxin-
interacting protein, which interacts with NLRP3 and participates in the activation of the
NLRP3 inflammasome (17). Because ATP activates the NLRP3 inflammasome, we then
evaluated the cell surface abundances of the ATP receptor P2X7R (9) and CD39, an
ectonucleotidase that hydrolyzes extracellular ATP (18); however, we found that they were
also not altered in Ifnar1−/− cells (fig. S4B). Next, we asked whether IFNAR signaling
inhibited the generation of molecules that activate the NLRP3 inflammasome. A major
activator of the NLRP3 inflammasome is ROS (19). We detected increased amounts of ROS
in Ifnar1−/− macrophages compared to those in wild-type macrophages after stimulation
with ATP (fig. S4C). Treatment with rIFN-a accordingly dampened ATP-induced ROS
generation in wild-type cells (Fig. 2A). These data suggested that IFNAR signaling
suppressed the generation of ROS generation. Mitochondria are considered to be the major
source of ROS that activate the NLRP3 inflammasome (20), but NADPH (reduced form of
nicotinamide adenine dinucleotide phosphate) oxidase also produces ROS. To confirm that
the treatment of cells with ATP induces ROS production from mitochondria, we measured
ROS generation with MitoSOX Red, an indicator of mitochondrial superoxide. We found
that the amount of mitochondrial ROS produced 30 min after stimulation with ATP was
maximal (fig. S5A). Treatment of macrophages with rIFN-α or rIFN-β suppressed the
generation of mitochondrial ROS 30 min after stimulation with ATP (fig. S5B). On the other
hand, the involvement of NADPH oxidase in IFN-β–mediated suppression of ROS was
negligible because we found no obvious inhibition of ROS generation or IL-1β production
in macrophages deficient in p47phox, a key component of NADPH oxidase (fig. S5, C and
D).
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An inhibitor of Rac1 suppresses the generation of ROS
Mitochondrial generation of ROS is induced by Rac1 (21), a member of the Rho family of
GTPases. We first confirmed that the generation of ROS and IL-1β by ATP was suppressed
by the Rac1 inhibitor NSC23766 in a dose-dependent manner (Fig. 2B and fig. S6, A and
B). We further ruled out a global effect of Rac1 inhibition on cytokine production by
showing that NSC23766 did not alter the abundances of Il1b, Tnfa, and Il6 mRNAs (fig.
S6C) or the amounts of tumor necrosis factor–α (TNF-α) and IL-6 proteins (fig. S6D).
Collectively, these data suggested that inhibition of Rac1 inhibited ROS generation, which
led to inhibition of NLRP3 inflammasome activation and decreased IL-1β generation.
IFNAR signaling inhibits Rac1 activation by SOCS1-mediated suppression of Vav1 and
Rac1-GTP
We observed that the stimulation of cells with ATP activated Rac1 but that the addition of
IFN-β prevented Rac1 activation, as determined by the measurement of the amount of Rac1
bound to GTP (Rac1-GTP), the active form of Rac1 (Fig. 2C). This result suggested that
IFN-β inhibited the activation of Rac1. Here, we found that the treatment of macrophages
with IFN-β resulted in reduced amounts of Vav1 protein, a guanine nucleotide exchange
factor (GEF) for Rac1 (fig. S7A), which suggested that Vav1 mediated the suppression of
Rac1 activation by IFN-β. Because SOCS1 mediates the degradation of Vav through
ubiquitination (22), we asked whether the suppression of Vav1 by IFN-β was mediated by
SOCS1. We found that IFNAR signaling induced Socs1 expression (Fig. 3A) and that
silencing of Socs1 mRNA with short hairpin RNA (shRNA) derepressed Vav1 expression in
wild-type macrophages (fig. S7B). These results suggested that IFNAR signaling suppresses
Vav1 through SOCS1. We also confirmed the efficacy of Socs1 silencing with shRNA (fig.
S7C). In addition, we found that SOCS1 directly suppressed Rac1-GTP by ubiquitin-
mediated degradation, as determined by coimmunoprecipitation of Rac1-GTP and SOCS1
(Fig. 3B and fig. S7D) and by the detection of the substantial ubiquitination ofRac1-GTP
(Fig. 3C). We found that derepression of Rac1-GTP and ROS generation was observed in
cells in which Socs1was silenced (Fig. 3, D and E). Furthermore, inhibition of IL-1β
production by IFN-β was partially reversed by silencing Socs1 (fig. S7E). Next, we asked
whether the NLRP3 inflammasome itself had a feedback effect on the abundances of
SOCS1, Vav1, Rac1-GTP, and ROS. First, we confirmed the failure of events downstream
of the NLRP3 inflammasome, such as caspase-1 activation and IL-1β generation, in
Nlrp3−/− macrophages and Asc−/− macrophages (fig. S8, A and B). On the other hand, the
abundances of SOCS1, Vav1, and Rac1-GTP and the generation of ROS were unchanged in
Nlrp3−/− and Asc−/− macrophages compared to those in wild-type macrophages (fig. S8, C
to G). These results suggested that molecules upstream of the NLRP3 inflammasome,
including SOCS1, Vav1, Rac1-GTP, and ROS, were regulated by IFNAR signaling and not
by the feedback effect of impaired or suppressed activity of the NLRP3 inflammasome. In
summary, IFNAR signaling induced SOCS1 activity, which inhibited Rac1 activation, ROS
generation, and eventually NLRP3 inflammasome activity (Fig. 3F).
EAE progression is induced by active NLRP3 inflammasome
Next, we sought to delineate the activation status of the NLRP3 inflammasome during EAE
progression. We found that whereas wild-type mice developed EAE, Asc−/− and Nlrp3−/−
mice did not (Fig. 4A). In wild-type mice with EAE, we detected a consistent increase in the
amount of serum IL-1β from day 0 to day 17 (disease peak) (Fig. 4B). This increase in
systemic IL-1β abundance in wild-type mice was entirely dependent on the NLRP3
inflammasome because IL-1β was undetectable in Asc−/− and Nlrp3−/− mice (Fig. 4B).
Similarly, increased amounts of serum IL-18 were observed in wild-type mice, but not in
Asc−/− and Nlrp3−/− mice, on day 9 (fig. S9). We also evaluated NLRP3 inflammasome
activity in mice by measuring the ability of splenocytes to exhibit IL-1β maturation. This
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was achieved by stimulating splenocytes with LPS alone, which induces the production of
pro–IL-1β but cannot activate the NLRP3 inflammasome. Splenocytes obtained on day 9
from immunized wild-type mice produced IL-1β upon stimulation with LPS (Fig. 4C),
suggesting that the NLRP3 inflammasome in splenocytes of immunized wild-type mice was
active. We also confirmed activation of the NLRP3 inflammasome by detecting caspase-1
p20 in wild-type splenocytes on day 9 after EAE induction (Fig. 4D).
IFN-β suppresses NLRP3 inflammasome activity and ameliorates EAE
We next asked whether IFN-β suppressed NLRP3 inflammasome activity in mice with EAE.
First, we confirmed the ex vivo efficacy of rIFN-β to induce expression of Socs1 and of
IFN-stimulated genes, such as Ip10 (Cxcl10) and Mx1, in macrophages (fig. S10). The
efficacy of rIFN-β in vivo was demonstrated by the amelioration of EAE (Fig. 4E). As
expected, rIFN-β reduced the amounts of serum IL-1β, the production of IL-1β by
splenocytes, and the generation of caspase-1 p20 protein in splenocytes (Fig. 4, F to H).
Consistent with these results, these parameters were increased in Ifnar1−/− mice compared to
those in wild-type mice (fig. S11). Collectively, these data suggest that rIFN-β suppresses
the NLRP3 inflammasome to ameliorate EAE.
Aggressive immunization induces a form of EAE that does not respond to IFN-β
We showed that either the lack of the NLRP3 inflammasome or the treatment with rIFN-β
protected mice from EAE; however, this situation still does not reflect the full complexity
observed in MS patients, one-third of whom fail to respond to IFN-β. In the EAE model
(Fig. 4), a mouse was injected with MOG (myelin oligodendrocyte glycoprotein) peptide in
complete Freund’s adjuvant (CFA) that contained 200 mg of heat-killed Mycobacteria
(Mtb), and a deficiency in NLRP3 or ASC protected mice from EAE. However, aggressive
immunization regimens induced EAE in Nlrp3−/− and Asc−/− mice in a manner that
depended on the dose of Mtb. We observed considerably severe EAE symptoms in Nlrp3−/−
and Asc−/− mice injected with 300 mg or more of Mtb, but no EAE in mice injected with
200 mg of Mtb (fig. S12). We then induced EAE in wild-type, Nlrp3−/− and Asc−/− mice
with 300 mg of Mtb and asked whether IFN-β ameliorated EAE. We found that IFN-β was
not effective against EAE in the Nlrp3−/− and Asc−/− mice, which have a defective NLRP3
inflammasome (Fig. 5, B and C). These findings suggested that the IFN-β treatment is not
effective when EAE progression is independent of the NLRP3 inflammasome.
Passive EAE induces NLRP3 inflammasome activation and can be treated by IFN-β
Mtb induces NLRP3 inflammasome activation (23). Therefore, we sought to delineate
whether the NLRP3 inflammasome is activated in EAE induced without CFA. To induce
passive EAE, we isolated CD4+ T cells from immunized mice and then intravenously
transferred them to naïve Rag2−/− and Rag2−/−Nlrp3−/− mice (Fig. 6A). Rag2−/− mice lack T
cells and B cells and are often used as T cell hosts in the induction of passive EAE. Rag2−/−
recipients developed EAE, but Rag2−/− Nlrp3−/− recipients did not (Fig. 6B), suggesting that
the passive EAE model was NLRP3 inflammasome–dependent. We next asked whether the
passive EAE model activated the NLRP3 inflammasome and whether IFN-β suppressed its
activity to ameliorate passive EAE. We confirmed the activation of the NLRP3
inflammasome in Rag2−/− recipients, but not in Rag2−/−Nlrp3−/− recipients, by detecting
IL-1β in the serum, measuring the ability of splenocytes to produce mature IL-1β, and by
detecting caspase-1 p20 (Fig. 6, C to E). In the spleen, macrophages in particular showed the
ability to induce the maturation of IL-1β (fig. S13). Rag2−/− recipients showed a substantial
response to IFN-β by ameliorating EAE (Fig. 6B), together with the inhibition of NLRP3
inflammasome activity (Fig. 6, C to E). We further observed that cells that had infiltrated the
brain in the context of passive EAE had the ability to induce IL-1β maturation (fig. S13),
suggesting that the NLRP3 inflammasome was activated in the brain as well as in the spleen.
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Together, these data suggest that theNLRP3 inflammasome can be activated in EAE induced
without CFA and that such EAE is ameliorated by treatment with IFN-β.
DISCUSSION
Here, we report two findings: First, that a suppressive mechanism of IFN-β on NLRP3
inflammasome activity is mediated by SOCS1, Vav1, Rac1-GTP, and the generation of
mitochondrial ROS generation, and second, that EAE can be divided into two subsets on the
basis of their dependency on the NLRP3 inflammasome; the NLRP3 independent form of
EAE cannot be treated with IFN-β.
Two studies showed that IFN-β suppresses IL-1β production (7, 8). One of the studies
showed that IL-27 mediates the inhibition of IL-1β production by IFN-β but did not
investigate the inhibitory mechanism of IL-27 (7). A possible mechanism by which IL-1β
production is suppressed by IL-27 is through the targeting of the first step of pro– IL-1β
generation by IL-27 receptor (IL-27R) signaling. In the study (7), cells were stimulated with
zymosan, which activates theNLRP3 inflammasome through signaling by the receptor
dectin-1 and the kinase Syk (24, 25). Therefore, the zymosan-activatedNLRP3
inflammasome is poised to process pro–IL-1β in this experimental system, but if IL-27R
signaling targets the production of pro–IL- 1b, then the scarce supply of pro–IL-1β would
inhibit the generation of IL-1β.
The second possibility is that IL-27R signaling targets the maturation of IL-1β by interfering
with the dectin-1–Syk–NLRP3 axis to inhibit the NLRP3 inflammasome (24, 25). If this is
the case, it will be of interest to determine whether IL-27 suppresses NLRP3 inflammasome
activation that is triggered by ATP. Whether Syk-mediated NLRP3 inflammasome activity
occurs during EAE progression is also an interesting question. Another study showed that
the autocrine effect of IL-10 mediates the suppression of pro–IL-1β production in response
to IFN-β, that is, by targeting the first step in pro–IL-1β generation (8). We did not observe
suppression of pro–IL-1β production by macrophages that had been preincubated for 24
hours with IFN-β before being stimulated for 3 hours with LPS. The same group also
showed suppression of NLRP3 inflammasome activity by IFN-β, whereby signal transducer
and activator of transcription 1 (STAT1), which signals downstream of IFNAR, mediated
the suppressive role (8). However, how IFNAR signaling inhibits NLRP3 inflammasome
activity was not described in that report; therefore, it is still unclear whether suppression of
NLRP3 inflammasome activated by alum and Candida, which are used in that study, is
mediated by the same pathway that we identified here. These previous studies and ours
suggest the presence of multiple mechanisms to inhibit IL-1β production. Because IL-1β is a
potent proinflammatory molecule that has a substantial effect on immunity, multiple layers
of mechanisms to suppress IL-1β may have been developed during evolution as protection
against excessive inflammation.
The intensity of the EAE-induction regimen determines the phenotypes of EAE. Two reports
described EAE in Nlrp3−/− mice, one of which concluded that NLRP3 plays a critical role
(26), whereas the other concluded that NLRP3 is not involved in the progression of EAE
(27). It appears that the EAE-induction regimens used were different in both reports. In
particular, aggressive EAE induction seems to have been performed in the study showing
that Nlrp3−/− mice develop severe EAE (27). The results from both reports may appear to be
conflicting, but we assume that the two distinct results reflect two different subtypes of
EAE. We showed that immunization with 300 mg of Mtb in CFA induced EAE in Asc−/−
and Nlrp3−/− mice, whereas immunization with 200 mg of Mtb in CFA failed to do so. As a
result of immunization with 300 mg of Mtb, wild-type mice developed slightly more severe
EAE than did Asc−/− and Nlrp3−/− mice (Fig. 5). This is probably because the intensity of
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immunization still enabled wild-type mice to develop NLRP3 inflammasome–dependent
EAE in addition to NLRP3 inflammasome–independent EAE. Indeed, in wild-type mice,
IFN-β was only partially efficacious in treating EAE induced with 300 mg of Mtb compared
to its effects on EAE induced with 200 mg of Mtb. As for Asc−/− and Nlrp3−/− mice, it is
possible that even more intensive induction of EAE, for example, with 300 to 400 mg of
Mtb, is required to develop EAE that is as severe as that observed in wild-type mice.
Although the efficacy of IFN-β was not tested, a similar phenomenon was observed in a
study of caspase-1–deficient mice, which do not develop EAE when immunized with a low
dose of antigenic peptide but do develop EAE with increased antigen dosage (28).
Therefore, it appears that intensive antigen presentation to T cells induces EAE in an
NLRP3 inflammasome–independent fashion.
We showed that a subtype of EAE, which did not respond to IFN-β, could be induced by
aggressive immunization. Stromnes et al. reported “atypical EAE,” which was induced in
major histocompatibility complex (MHC) congenic C3H mice (29). Such atypical EAE was
characterized by severe disease progression and an enhanced ratio of TH17 cells to TH1
cells in the central nervous system (29). The authors also demonstrated that the high TH17/
TH1 ratio correlated with the functional avidity of the antigenic peptide for MHC (29).
Atypical EAE, described in the study, may have similarities with EAE induced by
aggressive immunization (and that is NLRP3 inflammasome–independent) in terms of
intense T cell stimulation. Although the efficacy of IFN-β was not evaluated in the study of
atypical EAE, Axtell et al. showed that TH17-induced EAE cannot be treated by IFN-β (30).
At this point, it is not known whether the findings of Stromnes et al. (29) and Axtell et al.
(30) can be connected to ours. To do so, one must ask the following questions: Is atypical
EAE NLRP3 inflammasome–independent and does it not respond to IFN-β, and is NLRP3
inflammasome–independent EAE prone to develop a high TH17/TH1 ratio?
We are currently addressing why aggressive disease induction regimens can induce EAE
independently of the NLRP3 inflammasome. It is also important to elucidate the role of the
NLRP3 inflammasome in MS and to understand whether those patients who do not respond
to IFN-β therapy are those who have MS that developed in an NLRP3 inflammasome–
independent manner. A number of reports strongly suggest the involvement of
inflammasomes in the development of MS. For example, Furlan et al. showed the
involvement of caspase-1, a key component of inflammasomes, in MS (31), and Ming et al.
showed that caspase-1 was highly abundant in MS plaques (32). Huang et al. further
demonstrated the increased abundance of caspase-1 and IL-18 in peripheral mononuclear
cells from MS patients compared to those in cells from healthy controls (33). Therefore, we
suggest that it is likely that the NLRP3 inflammasome is involved in the pathogenicity of
MS. Here, we speculated that events in MS that are equivalent to aggressive immunization
might be severe infections or even severe sterile inflammation. In conclusion, we have
demonstrated a previously uncharacterized signaling pathway in which activation of the
NLRP3 inflammasome is inhibited by IFN-β, and we described a subset of EAE that does
not respond to IFN-β therapy. These findings may be a first step to exploring the possibility
of a new prognostic approach for the treatment of MS.
MATERIALS AND METHODS
Animals
Male mice of the C57BL/6 background were used in this study. Ifnar1−/− mice were
backcrossed to C57BL/6 mice for 12 generations. The Asc−/− and Nlrp3−/− mice were a gift
from Genentech and were rederived in our facility. C57BL/6 and 2D2 T cell receptor (TCR)
transgenic (Tg) mice were purchased from Jackson Laboratories. All of the mice were kept
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in a barrier facility. This study was approved by the Duke University Institutional Animal
Care and Use Committee.
Reagents, antibodies, and recombinant proteins
Ultrapure LPS (InvivoGen), which is highly purified LPS that does not activate
inflammasomes, was used throughout this study instead of regular LPS. ATP (used at a final
concentration of 5 mM unless otherwise noted) and nigericin were purchased from Sigma-
Aldrich. NSC23766 was purchased from Calbiochem. Antibody against caspase-1 p10 for
immunocytochemistry was purchased from Santa Cruz. Antibodies against Rac1 and Rac1-
GTP were from Millipore and New East Biosciences, respectively. Antibodies against Vav1
and ubiquitin were purchased from Cell Signaling. Mouse rIFN-α and rIFN-β were
purchased from Hycult and PBL, respectively. The rIFN-β used in the treatment of EAE was
human rIFN-β-1b (Betaseron). MOG35–55 peptide was synthesized by New England
Peptides. Enzyme-linked immunosorbent assay (ELISA) kits for the detection of IL-1β,
TNF, and IL-6 were purchased from BD PharMingen, and an ELISA kit for IL-18 was
purchased from Bender MedSystems.
Cell isolation and culture
Peritoneal macrophages were elicited by injection of mice with thioglycollate. Bone marrow
macrophages (BMMs) were derived by culturing bone marrow cells with L929 cell
supernatant. To detect NLRP3 inflammasome activity in splenocytes, we used ELISA to
measure IL-1β production by splenocytes, which were stimulated with Ultrapure LPS (100
ng/ml) for 24 hours. In the experiment, Opti-MEM medium was used for the cell culture.
We used complete RPMI medium unless otherwise noted. RNA and complementary DNA
preparation and qPCR analysis Total RNA was extracted from cells with TRIzol
(Invitrogen). Complementary DNA (cDNA) synthesis was performed with qScript cDNA
SuperMix (Quanta). Real-time, quantitative polymerase chain reaction (qPCR) analysis was
performed with KAPA SYBR FAST (Kapa Bio Systems) on the MyiQ PCR System (Bio-
Rad) with an initial denaturing step at 95°C for 3 min followed by 45 cycles of a
denaturation step at 94°C for 3 s and an annealing and extension step at 60°C for 30 s. The
relative amounts of qPCR products were determined with the DDCt method to compare the
relative expression of target genes and housekeeping genes. The expression of the gene
encoding b-actin was used as an internal control (34). Primer sequences can be found in
table S1.
Pull-down assays, immunoprecipitations, and Western blotting analysis
Rac1 activity was evaluated by performing a pull-down assay with the Rac1/Cdc42
activation assay kit (Millipore) as indicated by the supplier. To evaluate the physical
association between SOCS1 and Rac1-GTP, we performed coimmunoprecipitation
experiments with an antibody against Rac1-GTP and then used an antibody against SOCS1
to detect SOCS1 protein by Western blotting. To detect caspase-1 p20, we cultured
peritoneal macrophage or BMMs (5 × 106 cells) in Opti-MEM medium and treated them
with Ultrapure LPS (100 ng/ml) for 3 hours and then with 5 mM ATP for an additional hour.
To detect Vav1, we analyzed lysates from BMMs (5 × 106 cells) by Western blotting with
antibody against Vav1 (1:1000). Horseradish peroxidase (HRP)–conjugated secondary
antibody (1:1000, BD Pharmingen) was used to detect signals, which were visualized by
enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).
Analysis of caspase-1 foci formation
To activate caspase-1 (that is, the NLRP3 inflammasome), we incubated macrophages with
ATP for 30 min at 37°C. In some experiments, cells were treated with rIFN-α for 24 hours
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before ATP treatment. Cells were stained with anti–caspase-1 p10 antibody. After the
confocal microscopic images of cells were captured, the frequency (%) of caspase-1–
positive focus formation was calculated by enumerating the number of cells within a group
of 100 cells that had formed distinct caspase-1–positive foci. The integrated fluorescence
intensity was determined from at least 10 caspase-1–positive cells by digitally calculating
the pixel-to-pixel fluorescence intensity of caspase-1 staining. Statistical analysis was
performed on the results from four mice. Background was defined as the fluorescence
intensity in the cytoplasmic areas without caspase-1 focus formation.
Detection of ROS production
BMMs were stimulated with ATP for 30 min at 37°C before being harvested. In some
experiments, cells were pretreated with rIFN-β or NSC23766 (Rac1 inhibitor) for 24 hours
before being treated with ATP. ROS was detected by flow cytometry with either 2.5 mM
dihydroethidium (DHE, Biotium), 5 mM CM-H2DCFDA (Molecular Probes), or 5 mM
MitoSOX Red (Molecular Probes), which were added at same time as ATP.
Silencing SOCS1 with Socs1-specific shRNA
Cells were transfected with Socs1-specific shRNA or control shRNA expression vectors
(Santa Cruz). Four hours after transfection, cells were treated with rIFN-β for 24 hours. To
detect Rac1 activation or ROS generation, we added ATP for the last 10 or 30 min,
respectively.
Induction and evaluation of EAE
EAE induction was performed as previously described (2). Briefly, MOG35–55 peptide (100
mg per mouse) was emulsified with CFA (100 ml per mouse, including 200 mg of Mtb) and
subcutaneously injected into the flanks of mice on day 0. Mice were also intraperitoneally
injected with pertussis toxin (200 ng per mouse) on days 0 and 2. Mice were assessed daily
for clinical signs of EAE in a blinded fashion. In some experiments, we used higher dosages
of Mtb in CFA (100 ml per mouse, including indicated Mtb). To induce passive EAE, we
isolated CD4+ T cells from the spleens and lymph nodes of 2D2 TCR Tg mice 9 days after
MOG immunization and adoptively transferred them by intravenous injection into Rag2−/−
or Rag2−/−Nlrp3−/− recipient mice (2.5 × 106 cells per mouse). EAE scores were evaluated
on the basis of the following criteria: 1, tail limpness; 2, impaired righting reflex; 3,
hindlimb paralysis; 4, hind- and forelimb paralysis; 5, death.
Statistical analysis
Statistical analysis was evaluated with Student’s t tests or one-way analysis of variance
(ANOVA) analysis with the Tukey-Kramer method. The criterion of significance was set as
P < 0.05. All results are expressed as the means ± SEM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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IFNAR signaling suppresses activation of the NLRP3 inflammasome. (A) Wild-type (WT)
and Ifnar1−/− peritoneal macrophages were incubated for 3.5 hours with LPS alone (100 ng/
ml), 5 mM ATP alone, or a combination of LPS and ATP (ATP was added for the last 30
min), and the amount of IL -1β produced was measured. Representative data from three
independent experiments are shown. Data are the mean ± SEM from four mice. (B) Ifnar1−/−
macrophages exhibit increased amounts of active caspase-1 (Casp-1 p20). Cells were
incubated with or without LPS (100 ng/ml) for 3.5 h with ATP added for the last 30 or 60
min. Casp-1 p20 and β actin proteins were detected by Western blotting analysis of cell
culture supernatants and cell lysates, respectively. Western blots are representative of three
independent experiments. Densitometric analysis of pooled experiments are shown in the
bar graph. (C) Representative confocal microscopic images of caspase -1 (red) and DAPI
(blue) staining in WT and Ifnar−/− macrophages. Macrophages were incubated with or
without 5 mM ATP for 30 min at 37°C. Scale bar: 10 μm. Data are the mean ± SEM from
four experiments. (D) Frequencies of caspase -1 foci and integrated fluorescence intensities
(combined measure of staining area and intensity) of foci in WT and Ifnar1−/− macrophages.
Data are the mean ± SEM from four mice. *P < 0.05.
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IFNAR signaling suppresses Rac1-GTP. (A, B) ROS generation was evaluated by detecting
dihydroethidium (DHE) by flow cytometry. Data are the mean ± SEM from four
experiments. WT BMMs were treated with or with out rIFNα (1000 U/ml) for 24 hours,
with 5 mM ATP added for the last 30 min (A). Cells were pretreated with NSC23766 at the
indicated concentration s 24 h ours before treatment with ATP (B). (C) BMMs were
pretreated with IFN β (1000 U/ml) for 24 h ours before being treated with ATP for the
indicated times. Rac1-GTP was detected by Western blotting. Blots are representative of
four independent experiments. Densitometric analysis of the abundance of Rac1-GTP
normalized to that of total Rac1 from the four experiments is shown in the bar graph. The
sample that had the greatest amount of Rac1-GTP was set at a relative intensity value of 1.
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SOCS1 mediates the IFNAR-dependent suppression of Rac1 activation and ROS generation.
(A) Measurement of the relative abundance of Socs-1 mRNA in BMMs treated for 6 hours
with rIFNβ at the indicated concentrations. Data are the mean ± SEM from four
experiments. (B) Coimmunoprecipitation of Rac1-GTP and SOCS1 in BMMs 10 min after
treatment with ATP. Samples were subjected to immunoprecipitation (IP) with antibody
against Rac1-GTP and were analyzed by Western blotting (IB) with antibody against
SCOS1. (C) Ubiquitination was detected in a Rac1-GTP pull-down fraction obtained from
cells lysed 10 min after treatment with ATP. Samples were analyzed by Western blotting
with an antibody against ubiquitin. Data in (B) and (C) are representative of three
independent experiments. (D and E) Socs1 silencing derepresses the extent of (D) Rac1
activation (statistics from three independent experiments) and (E) ROS generation in
BMMs. Cells were transfected with plasmids encoding Socs1-specific shRNA (+) or control
shRNA (−). Four hours later, cells were treated with rIFNβ for 24 hours and stimulated with
ATP for the last 10 min. The Western blot in (D) is representative of three independent
experiments, and densitometric analysis of all experiments are shown in the bar graph. Data
shown in (E) are the mean ± SEM from four experiments. (F) Schematic model for type I
IFN mediated inhibition of the NLRP3 inflammasome through SOCS1-mediated inhibition
of ROS generation. *P < 0.05.
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IFNβ ameliorates EAE by suppressing NLRP3 inflammasome activity. (A) EAE was
induced and scored in WT, Asc−/−, and Nlrp3−/− mice as described in the Materials and
Methods. Data are from three independent experiments. (B) Serum IL-1β concentrations in
mice on the indicated days after EAE induction. (C) Splenocytes were isolated from mice 9
days after EAE induction, and were then treated in vitro with LPS for 24 hours. The amount
of IL-1β in the culture supernatant was determined by ELISA. (D) Detection of caspase-1
p20 in splenocyte culture supernatant 24 hours after cells were plated without stimulation. β-
actin was detected in corresponding cell lysates. Western blots are representative of five
independent experiments, and densitometric analysis of all experiments is shown in the bar
graph. (E to H) EAE was induced in (E) WT mice, as described for (A), and mice were
treated intraperitoneally with or without rIFN β (3 × 104 unit/mouse) on every other day
from day 0 to 10. IL -1β concentrations in (F) serum and (G) culture supernatants of
splenocytes, which were treated as described for (C), are shown from mice 9 days after
induction of EAE. (H) Caspase-1 p20 was detected by Western blotting analysis of
splenocytes from mice 9 days after induction of EAE in four independent experiments. Data
shown are the mean ± SEM of 5 mice for each group, unless otherwise noted. *P < 0.05.
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rIFNβ ameliorates the severity of EAE, but only when disease progression is mediated by
the NLRP3 inflammasome. (A to C) EAE was induced with CFA including 300 μg of Mtb.
(A) WT, (B) Nlrp3−/, and (C) Asc−/− mice were treated intraperitoneally with rIFNβ (3 ×
10 4 unit/mouse) every other day from day 0 to day 10 after induction of EAE. Disease
scores are presented as the mean ± SEM for each group (n=4 to 6 mice). Data are
representative of at least two independent experiments. *P < 0.05. N. S., not significant.
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Passive EAE develops in an NLRP3 inflammasome dependent fashion and responds to
IFNβ. (A) Schematic procedure for the induction of passive EAE. CD4+ T cells were
obtained from immunized 2D2 TCR Tg mice and were transferred to Rag2−/− or Rag2−/−
Nlrp3−/− recipient mice. Some Rag2−/− mice were treated intraperitoneally with rIFNβ (3 ×
104 unit/mouse) every third day between day 0 and day 15 after adoptive transfer of the T
cells. (B) Development of passive EAE. Disease scores are presented as the mean ± SEM for
each group (n = 4 to 5 mice). (C) IL-1β concentrations in serum on day 23 after T cell
transfer. (D) IL-1β production by splenocytes stimulated with LPS in vitro. (E) Detection of
caspase-1 p20 in splenocytes isolated from Rag2−/− mice that were untreated or were treated
with rIFNβ, and from Rag2−/− Nlrp3−/− mice. Data are the mean ± SEM from three
experiments unless otherwise noted. *P < 0.05.
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